Jukka Jokinen1, J Anthony G Scott. 1. Department of Vaccination and Immune Protection, National Institute for Health and Welfare, Helsinki, Finland.
Abstract
BACKGROUND: Community-acquired pneumonia is a common cause of hospitalization among African adults, and Streptococcus pneumoniae is assumed to be a frequent cause. Pneumococcal conjugate vaccine is currently being introduced into childhood immunization programs in Africa. The case for adult vaccination is dependent on the contribution of the pneumococcus to the hospital pneumonia burden. METHODS: Pneumococcal diagnosis is complex because there is no gold standard, and culture methods are invalidated by antibiotic use. We used latent class analysis to estimate the proportion of pneumonia episodes caused by pneumococcus. Furthermore, we extended this methodology to evaluate the effect of antimicrobial treatment on test accuracies and the prevalence of the disease. The study combined data from 5 validation studies of pneumococcal diagnostic tests performed on 281 Kenyan adults with pneumonia. RESULTS: The proportion of pneumonia episodes attributable to pneumococcus was 0.46 (95% confidence interval = 0.36-0.57). Failure to account for the effect of antimicrobial exposure underestimates this proportion as 0.32. A history of antibiotic exposure was a poor predictor of antimicrobial activity in patients' urine. Blood culture sensitivity for pneumococcus was estimated at 0.24 among patients with antibiotic exposure, and 0.75 among those without. CONCLUSIONS: The large contribution of pneumococcus to adult pneumonia provides a strong case for the investigation of pneumococcal vaccines in African adults.
BACKGROUND: Community-acquired pneumonia is a common cause of hospitalization among African adults, and Streptococcus pneumoniae is assumed to be a frequent cause. Pneumococcal conjugate vaccine is currently being introduced into childhood immunization programs in Africa. The case for adult vaccination is dependent on the contribution of the pneumococcus to the hospital pneumonia burden. METHODS:Pneumococcal diagnosis is complex because there is no gold standard, and culture methods are invalidated by antibiotic use. We used latent class analysis to estimate the proportion of pneumonia episodes caused by pneumococcus. Furthermore, we extended this methodology to evaluate the effect of antimicrobial treatment on test accuracies and the prevalence of the disease. The study combined data from 5 validation studies of pneumococcal diagnostic tests performed on 281 Kenyan adults with pneumonia. RESULTS: The proportion of pneumonia episodes attributable to pneumococcus was 0.46 (95% confidence interval = 0.36-0.57). Failure to account for the effect of antimicrobial exposure underestimates this proportion as 0.32. A history of antibiotic exposure was a poor predictor of antimicrobial activity in patients' urine. Blood culture sensitivity for pneumococcus was estimated at 0.24 among patients with antibiotic exposure, and 0.75 among those without. CONCLUSIONS: The large contribution of pneumococcus to adult pneumonia provides a strong case for the investigation of pneumococcal vaccines in African adults.
Authors: J A Scott; A J Hall; C Muyodi; B Lowe; M Ross; B Chohan; K Mandaliya; E Getambu; F Gleeson; F Drobniewski; K Marsh Journal: Lancet Date: 2000-04-08 Impact factor: 79.321
Authors: F T Cutts; S M A Zaman; G Enwere; S Jaffar; O S Levine; J B Okoko; C Oluwalana; A Vaughan; S K Obaro; A Leach; K P McAdam; E Biney; M Saaka; U Onwuchekwa; F Yallop; N F Pierce; B M Greenwood; R A Adegbola Journal: Lancet Date: 2005 Mar 26-Apr 1 Impact factor: 79.321
Authors: Werner C Albrich; Shabir A Madhi; Peter V Adrian; Jean-Noel Telles; Glaucia Paranhos-Baccalà; Keith P Klugman Journal: J Clin Microbiol Date: 2014-09-24 Impact factor: 5.948
Authors: Werner C Albrich; Michael W Pride; Shabir A Madhi; Jan Callahan; Peter V Adrian; Roger French; Nadia van Niekerk; Shite Sebastian; Victor Souza; Jean-Noel Telles; Glaucia Paranhos-Baccalà; Kathrin U Jansen; Keith P Klugman Journal: J Clin Microbiol Date: 2016-12-28 Impact factor: 5.948
Authors: W C Albrich; S A Madhi; P V Adrian; N van Niekerk; T Mareletsi; C Cutland; M Wong; M Khoosal; A Karstaedt; P Zhao; A Deatly; M Sidhu; K U Jansen; K P Klugman Journal: Clin Infect Dis Date: 2011-12-08 Impact factor: 9.079
Authors: A Saukkoriipi; A A Palmu; J Jokinen; V Verlant; W P Hausdorff; T M Kilpi Journal: Eur J Clin Microbiol Infect Dis Date: 2014-11-21 Impact factor: 3.267
Authors: Daniel R Feikin; M Kariuki Njenga; Godfrey Bigogo; Barrack Aura; George Aol; Allan Audi; Geoffrey Jagero; Peter Ochieng Muluare; Stella Gikunju; Leonard Nderitu; Amanda Balish; Jonas Winchell; Eileen Schneider; Dean Erdman; M Steven Oberste; Mark A Katz; Robert F Breiman Journal: PLoS One Date: 2012-08-24 Impact factor: 3.240
Authors: Maria A Said; Hope L Johnson; Bareng A S Nonyane; Maria Deloria-Knoll; Katherine L O'Brien; Felipe Andreo; Bojana Beovic; Silvia Blanco; Wim G Boersma; David R Boulware; Jay C Butler; Jordi Carratalà; Feng-Yee Chang; Patrick G P Charles; Alejandro A Diaz; Jose Domínguez; Naomi Ehara; Henrik Endeman; Vicenç Falcó; Miquel Falguera; Kiyoyasu Fukushima; Carolina Garcia-Vidal; Daniel Genne; Igor A Guchev; Felix Gutierrez; Susanne S Hernes; Andy I M Hoepelman; Ulla Hohenthal; Niclas Johansson; Vitezslav Kolek; Roman S Kozlov; Tsai-Ling Lauderdale; Ivana Mareković; Mar Masiá; Matta A Matta; Òscar Miró; David R Murdoch; Eric Nuermberger; Richard Paolini; Rafael Perelló; Dominic Snijders; Vanda Plečko; Roger Sordé; Kristoffer Strålin; Menno M van der Eerden; Angel Vila-Corcoles; James P Watt Journal: PLoS One Date: 2013-04-02 Impact factor: 3.240